---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002866"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:30:35.292188+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q1 net loss $7.8M; cash $175M funds operations into 2026

## Summary
- Net loss of $7.8M ($0.06 per share) vs $7.2M in Q1 2022; R&D spend up 50% to $6.6M on CTX-009.
- Cash and marketable securities $175M at March 31, 2023, providing runway into 2026.
- Phase 2/3 of CTX-009 in biliary tract cancers enrolling; top-line data expected H1 2024.
- Phase 2 CTX-009 in colorectal cancer initial data expected Q3 2023; ASCO GI data showed 37.5% ORR.
- Appointed Minori Rosales as SVP Head of Clinical Development and Richard Lindahl to board as Audit Chair.

## SEC filing metadata
- accession: 0001171843-23-002866
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/0001171843-23-002866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/f8k_050323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002866
- JSON: https://secwatch.observer/filing/0001171843-23-002866.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002866.txt

## Key facts
- Earnings Releases
  Compass Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $7.8 million, EPS $0.06 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $7.8 million
  - EPS: $0.06 per share
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2023, was $7.8 million or $0.06 per share, compared to $7.2 million or $0.07 per share for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/0001171843-23-002866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.